Fat and iron quantification in the liver: Past, present, and future

Topics in Magnetic Resonance Imaging

Volumn 23, Issue 2, 2014, Pages 129-150

  Yokoo, Takeshi ^a,b   Browning, Jeffrey D ^b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

fat fraction; fatty liver; hemochromatosis; iron overload; proton density; quantitative imaging; relaxometry; steatosis

Indexed keywords

CARBENE; FAT; FERRITIN; HEMOSIDERIN; HYDROGEN; IRON; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL;

AMBIGUITY; ARTICLE; ARTIFACT; BREATHING FREQUENCY MONITOR; CALIBRATION; CELL MEMBRANE; FATTY LIVER; HEMOCHROMATOSIS; HUMAN; IMAGING; IRON OVERLOAD; LIVER; LIVER LEVEL; LIVER PARENCHYMA; MAGNETIC FIELD; MATHEMATICAL MODEL; MEASUREMENT ERROR; MEMBRANE DAMAGE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARASPINAL MUSCLE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RADIOFREQUENCY; REPRODUCIBILITY; SIGNAL NOISE RATIO;

EID: 84898475582     PISSN: 08993459     EISSN: 15361004     Source Type: Journal    
DOI: 10.1097/RMR.0000000000000016     Document Type: Article

References (209)

1. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol. 2003;15:539-543. (Pubitemid 36571048)
2. Brunt EM. Pathology of hepatic iron overload. Semin Liver Dis. 2005;25:392-401. (Pubitemid 41741256)
3. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500. (Pubitemid 32164902)
4. Perrault J, McGill DB, Ott BJ, et al. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology. 1978;74:103-106. (Pubitemid 8248893)
5. Cholongitas E, Senzolo M, Standish R, et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol. 2006;125:710-721.
6. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986;1:523-525. (Pubitemid 16138427)
7. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898-1906. (Pubitemid 40824701)
8. Ambu R, Crisponi G, Sciot R, et al. Uneven hepatic iron and phosphorus distribution in beta-thalassemia. J Hepatol. 1995;23:544-549.
9. Crisponi G, Ambu R, Cristiani F, et al. Does iron concentration in a liver needle biopsy accurately reflect hepatic iron burden in beta-thalassemia? Clin Chem. 2000;46(pt 1):1185-1188. (Pubitemid 30643324)
10. Emond MJ, Bronner MP, Carlson TH, et al. Quantitative study of the variability of hepatic iron concentrations. Clin Chem. 1999;45:340-346. (Pubitemid 29114168)
11. Villeneuve JP, Bilodeau M, Lepage R, et al. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol. 1996;25:172-177. (Pubitemid 26276629)
12. Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998;11:560-565. (Pubitemid 28280720)
13. Cobbold JF, Anstee QM, Taylor-Robinson SD. The importance of fatty liver disease in clinical practice. Proc Nutr Soc. 2010;69:518-527.
14. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202-1219. (Pubitemid 36538699)
15. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384.
16. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705-1725. (Pubitemid 35231670)
17. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44-52. (Pubitemid 40911310)
18. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013;178:38-45.
19. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462-E468. (Pubitemid 40110657)
20. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395. (Pubitemid 39657013)
21. Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593-608.
22. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203.
23. Brunt EM, Tiniakos DG. Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:691-707.
24. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:521-533. (Pubitemid 39141140)
25. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249-1253.
26. Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61:141-152.
27. Ibrahim SH, Kohli R, Gores GJ. Mechanisms of lipotoxicity in NAFLD and clinical implications. J Pediatr Gastroenterol Nutr. 2011;53:131-140.
28. Neuschwander-Tetri BA. Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr Gastroenterol Rep. 2010;12:49-56.
29. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873. (Pubitemid 46489550)
30. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51:1947-1953.
31. Stepanova M, Younossi ZM. Independent Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in the US Population. Clin Gastroenterol Hepatol.
32. Bhatia LS, Curzen NP, Calder PC, et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012.
33. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.
34. Muhidin SO, Magan AA, Osman KA, et al. The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome. J Obes. 2012;2012:637538.
35. Bugianesi E. Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther. 2005;22(suppl 2):40-43. (Pubitemid 41564381)
36. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40:484-490. (Pubitemid 38230851)
37. Bjornsson E. Angulo P. Hepatitis C and steatosis. Arch Med Res. 2007;38:621-627. (Pubitemid 47001562)
38. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636-1642.
39. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation. 1993;55:807-813. (Pubitemid 23122053)
40. Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg. 2009;16:137-144.
41. Vetelainen R, van Vliet A, Gouma DJ, et al. Steatosis as a risk factor in liver surgery. Ann Surg. 2007;245:20-30. (Pubitemid 46035431)
42. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-2474. (Pubitemid 29420675)
43. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321. (Pubitemid 40770284)
44. Longo R, Pollesello P, Ricci C, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging. 1995;5:281-285.
45. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol. 1999;276(pt 1):E977-E989. (Pubitemid 29249618)
46. Reeder SB, Hu HH, Sirlin CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging. 2012;36:1011-1014.
47. Ligabue G, Besutti G, Scaglioni R, et al. MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends. Quant Imaging Med Surg, 2013;3:192-195.
48. Hu HH, Bornert P, Hernando D, et al. ISMRM workshop on fat-water separation: insights, applications and progress inMRI. Magn Reson Med. 2012;68:378-388.
49. Le TA, Chen J, Changchien C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology. 2012;56:922-932.
50. Gastaldelli A, Harrison S, Belfort-Aguiar R, et al. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther. 2010;32:769-775.
51. Ramon-Krauel M, Salsberg SL, Ebbeling CB, et al. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013;9:252-260.
52. Dixon WT. Simple proton spectroscopic imaging. Radiology. 1984;153:189-194. (Pubitemid 14043406)
53. Lee JK, Dixon WT, Ling D, et al. Fatty infiltration of the liver: demonstration by proton spectroscopic imaging. Preliminary observations. Radiology. 1984;153:195-201. (Pubitemid 14043407)
54. Heiken JP, Lee JK, Dixon WT. Fatty infiltration of the liver: evaluation by proton spectroscopic imaging. Radiology. 1985;157:707-710. (Pubitemid 16232114)
55. Mitchell DG, Kim I, Chang TS, et al. Fatty liver. Chemical shift phase-difference and suppression magnetic resonance imaging techniques in animals, phantoms, and humans. Invest Radiol. 1991;26:1041-1052.
56. Low RN, Francis IR, Herfkens RJ, et al. Fast multiplanar spoiled gradient-recalled imaging of the liver: pulse sequence optimization and comparison with spin-echo MR imaging. AJR Am J Roentgenol. 1993;160:501-509. (Pubitemid 23074847)
57. Skinner TE, Glover GH. An extended two-point Dixon algorithm for calculating separate water, fat, and B0 images. Magn Reson Med. 1997;37:628-630. (Pubitemid 27146844)
58. Wang Y, Li D, Haacke EM, et al. A three-point Dixon method for water and fat separation using 2D and 3D gradient-echo techniques. J Magn Reson Imaging. 1998;8:703-710. (Pubitemid 28267795)
59. Glover GH, Schneider E. Three-point Dixon technique for true water/fat decomposition with B0 inhomogeneity correction. Magn Reson Med. 1991;18:371-383.
60. Kim YS, Mun CW, Cho ZH. Chemical-shift imaging with large magnetic field inhomogeneity. Magn Reson Med. 1987;4:452-460. (Pubitemid 17108570)
61. Qayyum A, Goh JS, Kakar S, et al. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques-initial experience. Radiology. 2005;237:507-511. (Pubitemid 41507887)
62. Cowin GJ, Jonsson JR, Bauer JD, et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging. 2008;28:937-945.
63. Cotler SJ, Guzman G, Layden-Almer J, et al. Measurement of liver fat content using selective saturation at 3.0 T. J Magn Reson Imaging. 2007;25:743-748. (Pubitemid 46516726)
64. Kwok WE, Totterman SM, Zhong J. Interleaved water and fat dual-echo spin echo imaging with intrinsic chemical-shift elimination. J Magn Reson Imaging. 2001;13:318-323. (Pubitemid 32066672)
65. Hernando D, Haldar JP, Sutton BP, et al. Joint estimation of water/fat images and field inhomogeneity map. Magn Reson Med. 2008;59:571-580. (Pubitemid 351348228)
66. Reeder SB, Pineda AR, Wen Z, et al. Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): application with fast spin-echo imaging. Magn Reson Med. 2005;54:636-644. (Pubitemid 41233758)
67. Ma J, Vu AT, Son JB, et al. Fat-suppressed three-dimensional dual echo Dixon technique for contrast agent enhanced MRI. J Magn Reson Imaging. 2006;23:36-41. (Pubitemid 43100716)
68. Eggers H, Brendel B, Duijndam A, et al. Dual-echo Dixon imaging with flexible choice of echo times. Magn Reson Med, 2011;65:96-107.
69. Rosenkrantz AB, Mannelli L, Kim S, et al. Gadolinium-enhanced liver magnetic resonance imaging using a 2-point Dixon fat-water separation technique: impact upon image quality and lesion detection. J Comput Assist Tomogr. 2011;35:96-101.
70. Reeder SB, Cruite I, Hamilton G, et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging. 2011;34.
71. de Bazelaire CM, Duhamel GD, Rofsky NM, et al. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology. 2004;230:652-659. (Pubitemid 38252858)
72. Fishbein MH, Gardner KG, Potter CJ, et al. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging. 1997;15:287-293. (Pubitemid 27280484)
73. Yokoo T, Collins JM, Hanna RF, et al. Effects of intravenous gadolinium administration and flip angle on the assessment of liver fat signal fraction with opposed-phase and in-phase imaging. J Magn Reson Imaging. 2008;28:246-251. (Pubitemid 351956490)
74. Bydder M, Yokoo T, Hamilton G, et al. Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging. 2008;26:347-359.
75. Liu CY, McKenzie CA, Yu H, et al. Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise. Magn Reson Med. 2007;58:354-364. (Pubitemid 47267653)
76. Pilleul F, Chave G, Dumortier J, et al. Fatty infiltration of the liver. Detection and grading using dual T1 gradient echo sequences on clinical MR system.Gastroenterol Clin Biol. 2005;29:1143-1147. (Pubitemid 43046359)
77. Hollingsworth KG, Joubert I, Lomas DJ. Assessment of diffuse liver disease by MR diffusion measurement: influence of perfustion. Proc Int Soc Magn Reson Med. 2005;13:1892.
78. Westphalen AC, Qayyum A, Yeh BM, et al. Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. Radiology. 2007;242:450-455. (Pubitemid 46146198)
79. Pacifico L, Celestre M, Anania C, et al. MRI and ultrasound for hepatic fat quantification:relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease. Acta Paediatr. 2007;96:542-547. (Pubitemid 46466114)
80. Johnson BL, Schroeder ME,Wolfson T, et al. Effect of flip angle on the accuracy and repeatability of hepatic proton density fat fraction estimation by complex data-based, T1-independent, T2-corrected, spectrum-modeled MRI. J Magn Reson Imaging. 2013.
81. Hussain HK, Chenevert TL, Londy FJ, et al. Hepatic fat fraction: MR imaging for quantitative measurement and display-early experience. Radiology. 2005;237:1048-1055. (Pubitemid 41636400)
82. Yang IY, Cui Y, Wiens CN, et al. Fat fraction bias correction using T estimates and flip angle mapping. J Magn Reson Imaging. 2013.
83. Yu H, Shimakawa A, McKenzie CA, et al. Multiecho water-fat separation and simultaneous R2 estimation with multifrequency fat spectrum modeling. Magn Reson Med. 2008;60:1122-1134.
84. O'Regan DP, Callaghan MF, Wylezinska-Arridge M, et al. Liver fat content and T2: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0 T-feasibility. Radiology. 2008;247:550-557.
85. Brix G, Heiland S, Bellemann ME, et al. MR imaging of fat-containing tissues: valuation of two quantitative imaging techniques in comparison with localized proton spectroscopy. Magn Reson Imaging. 1993;11:977-991.
86. Brix G, Schad LR, Lorenz WJ. Evaluation of proton density by magnetic resonance imaging: phantom experiments and analysis of multiple component proton transverse relaxation. Phys Med Biol. 1990;35:53-66. (Pubitemid 20029077)
87. Yokoo T, Barksdale J, Bydder M, et al. Effects of T1, T2, and spectral complexity on in-and out-of-phase imaging: a systematic approach by computer simulation. In: Joint Annual Meeting ISMRM-ESMRMB. Berlin, Germany: 2007.
88. Yokoo T, Bydder M, Hamilton G, et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology. 2009;251:67-76.
89. Reeder SB, Robson PM, Yu H, et al. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging. 2009;29:1332-1339.
90. Hamilton G, Yokoo T, Bydder M, et al. In vivo characterization of the liver fat (1)H MR spectrum. NMR Biomed. 2011;24:784-790.
91. Ren J, Dimitrov I, Sherry AD, et al. Composition of adipose tissue and marrow fat in humans by 1H NMR at 7 Tesla. J Lipid Res. 2008;49:2055-2062.
92. Kijowski R, Woods MA, Lee KS, et al. Improved fat suppression using multipeak reconstruction for IDEAL chemical shift fat-water separation: application with fast spin echo imaging. J Magn Reson Imaging. 2009;29:436-442.
93. Yokoo T, Shiehmorteza M, Bydder M, et al. Spectrally-modeled hepatic fat quantification by multi-echo gradient-recalled-echo magnetic resonance imaging at 3.0T. In: Proceedings 17th Scientific Meeting, International Society for Magnetic Resonance in Medicine. Honolulu, Hawaii: 2009.
94. Yokoo T, Shiehmorteza M, Hamilton G, et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology. 2011;258:749-759.
95. Meisamy S, Hines CD, Hamilton G, et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology. 2011;258:767-775.
96. Hines CD, Yu H, Shimakawa A, et al. T1 independent, T2 corrected MRI with accurate spectral modeling for quantification of fat: validation in a fat-water-SPIO phantom. J Magn Reson Imaging. 2009;30:1215-1222.
97. Zhong L, Chen JJ, Chen J, et al. Nonalcoholic fatty liver disease: quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy. J Dig Dis. 2009;10:315-320.
98. Negrete LM, Middleton MS, Clark L, et al. Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects. J Magn Reson Imaging. 2013.
99. Mashhood A, Railkar R, Yokoo T, et al. Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. J Magn Reson Imaging. 2013;37:1359-1370.
100. Bydder M, Shiehmorteza M, Yokoo T, et al. Assessment of liver fat quantification in the presence of iron. Magn Reson Imaging. 2010;28:767-776.
101. Liau J, Shiehmorteza M, Girard OM, et al. Evaluation of MRI fat fraction in the liver and spine pre and post SPIO infusion. Magn Reson Imaging. 2013;31:1012-1016.
102. Permutt Z, Le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease-MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36:22-29.
103. Tang A, Tan J, Sun M, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013;267:422-431.
104. Idilman IS, Aniktar H, Idilman R, et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology. 2013;267:767-775.
105. Kuhn JP, Hernando D, Munoz del Rio A, et al. Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology. 2012;265:133-142.
106. Reeder S, Hines C, Yu H, et al. On the definition of fat-fraction for in vivo fat quantification with magnetic resonance imaging. In: Proceedings 17th Scientific Meeting, International Society for Magnetic Resonance in Medicine. Honolulu, Hawaii: 2009.
107. Hu HH, Li Y, Nagy TR, et al. Quantification of absolute fat mass by magnetic resonance imaging: a validation study against chemical analysis. Int J Body Compos Res. 2011;9:111-122.
108. Bydder M, Girard O, Hamilton G. Mapping the double bonds in triglycerides. Magn Reson Imaging. 2011;29:1041-1046.
109. Peterson P, Mansson S. Simultaneous quantification of fat content and fatty acid composition using MR imaging. Magn Reson Med. 2013;69:688-697.
110. Berglund J, Ahlstrom H, Kullberg J. Model-based mapping of fat unsaturation and chain length by chemical shift imaging-phantom validation and in vivo feasibility. Magn Reson Med. 2012;68:1815-1827.
111. O'Regan DP, Callaghan MF, Wylezinska-Arridge M, et al. Liver fat content and T2: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0 T-feasibility. Radiology. 2008.
112. Hernando D, Liang ZP, Kellman P. Chemical shift-based water/fat separation: a comparison of signal models. Magn Reson Med. 2010;64:811-822.
113. Horng DE, Hernando D, Hines CD, et al. Comparison of R2correction methods for accurate fat quantification in fatty liver. J Magn Reson Imaging. 2013;37:414-422.
114. Bolan PJ, Arentsen L,Sueblinvong T, et al. Water-fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients. J Magn Reson Imaging, 2013;38:1578-1584.
115. Regis-Arnaud A, Guiu B, Walker PM, et al. Bone marrow fat quantification of osteoporotic vertebral compression fractures: comparison of multi-voxel proton MR spectroscopy and chemical-shift gradient-echo MR imaging. Acta Radiol. 2011;52:1032-1036.
116. Nardo L, Karampinos DC, Lansdown DA, et al. Quantitative assessment of fat infiltration in the rotator cuff muscles using water-fat MRI. J Magn Reson Imaging. 2013.
117. Fischer MA, Nanz D, Shimakawa A, et al. Quantification of muscle fat in patients with low back pain: comparison of multi-echo MR imaging with single-voxel MR spectroscopy. Radiology. 2013;266:555-563.
118. Liu CY, Redheuil A, Ouwerkerk R, et al. Myocardial fat quantification in humans: Evaluation by two-point water-fat imaging and localized proton spectroscopy. Magn Reson Med. 2010;63:892-901.
119. Goldfarb JW, Roth M, Han J. Myocardial fat deposition after left ventricular myocardial infarction: assessment by using MR water-fat separation imaging. Radiology. 2009;253:65-73.
120. Schwenzer NF, Machann J, Martirosian P, et al. Quantification of pancreatic lipomatosis and liver steatosis by MRI: comparison of in/opposed-phase and spectral-spatial excitation techniques. Invest Radiol. 2008;43:330-337. (Pubitemid 351572210)
121. Hamilton G, Smith DL Jr, Bydder M, et al. MR properties of brown and white adipose tissues. J Magn Reson Imaging. 2011;34:468-473.
122. Hu HH, Yin L, Aggabao PC, et al. Comparison of brown and white adipose tissues in infants and children with chemical-shift-encoded water-fat MRI. J Magn Reson Imaging. 2013;38:885-896.
123. Iancu TC. Ferritin and hemosiderin in pathological tissues. Electron Microsc Rev. 1992;5:209-229.
124. Crownover BK, Covey CJ. Hereditary hemochromatosis. Am Fam Physician. 2013;87:183-190.
125. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis. 2005;25:433-449. (Pubitemid 41741260)
126. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica. 2008;93:741-752. (Pubitemid 351669315)
127. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood. 2003;101:15-19. (Pubitemid 36025881)
128. Tsitsikas DA, Nzouakou R, Ameen V, et al. Comparison of serial serum ferritin measurements and liver iron concentration assessed by MRI in adult transfused patients with sickle cell disease. Eur J Haematol. 2013.
129. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985;313:1256-1262. (Pubitemid 16217048)
130. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761. (Pubitemid 27121266)
131. Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 2011;54:328-343.
132. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology. 1986;6:24-29. (Pubitemid 16137838)
133. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120:3657-3669.
134. Brown DW, Henkelman RM, Poon PY, et al. Nuclear magnetic resonance study of iron overload in liver tissue. Magn Reson Imaging1985;3:275-282. (Pubitemid 16193150)
135. Billotey C, Wilhelm C, Devaud M, et al. Cell internalization of anionic maghemite nanoparticles: quantitative effect on magnetic resonance imaging. Magn Reson Med. 2003;49:646-654. (Pubitemid 36389974)
136. Brass SD, Chen NK, Mulkern RV, et al. Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging. 2006;17:31-40. (Pubitemid 46672931)
137. Drayer B, Burger P, Darwin R, et al. MRI of brain iron. AJR Am J Roentgenol. 1986;147:103-110. (Pubitemid 16066336)
138. Stark DD, Moseley ME, Bacon BR, et al. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology. 1985;154:137-142. (Pubitemid 15196301)
139. Mazza P, Giua R, De Marco S, et al. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Haematologica. 1995;80:398-404.
140. Bonetti MG, Castriota-Scanderbeg A, Criconia GM, et al. Hepatic iron overload in thalassemic patients: proposal and validation of an MRI method of assessment. Pediatr Radiol. 1996;26:650-656. (Pubitemid 26316159)
141. Ernst O, Sergent G, Bonvarlet P, et al. Hepatic iron overload: diagnosis and quantification with MR imaging. AJR Am J Roentgenol. 1997;168:1205-1208. (Pubitemid 27183793)
142. Gandon Y, Guyader D, Heautot JF, et al. Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology. 1994;193:533-538.
143. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357-362. (Pubitemid 38169542)
144. Rose C, Vandevenne P, Bourgeois E, et al. Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients. Eur J Haematol. 2006;77:145-149.
145. Thomsen C, Wiggers P, Ring-Larsen H, et al. Identification of patients with hereditary haemochromatosis by magnetic resonance imaging and spectroscopic relaxation time measurements. Magn Reson Imaging. 1992;10:867-879. (Pubitemid 23082019)
146. Ooi GC, Khong PL, Chan GC, et al. Magnetic resonance screening of iron status in transfusion-dependent beta-thalassaemia patients. Br J Haematol. 2004;124:385-390. (Pubitemid 38167991)
147. Thomsen C, Jensen KE, Jensen M, et al. MR pulse sequences for selective relaxation time measurements: a phantom study. Magn Reson Imaging. 1990;8:43-50. (Pubitemid 20175239)
148. Papakonstantinou OG, Maris TG, Kostaridou V, et al. Assessment of liver iron overload by T2-quantitative magnetic resonance imaging: correlation of T2-QMRI measurements with serum ferritin concentration and histologic grading of siderosis. Magn Reson Imaging. 1995;13:967-977.
149. Clark PR, Chua-anusorn W, St Pierre TG. Bi-exponential proton transverse relaxation rate (R2) image analysis using RF field intensity-weighted spin density projection: potential for R2 measurement of iron-loaded liver. Magn Reson Imaging. 2003;21:519-530. (Pubitemid 36899085)
150. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855-861. (Pubitemid 40070775)
151. Senegas J, Knopp T, Dahnke H. Dealing with spatially varying noise in T2mapping with SENSE. In: Proceedings of the International Society of Magnetic Resonance in Medicine. Berlin, Germany: 2007.
152. Yokoo T, Yuan Q, Dimitrov I. Systematic investigation of various strategies for T2mapping for liver iron quantification in the presence of noise. In: Proceedings of the International Society of Magnetic Resonance in Medicine. 2013.
153. Chan WC, Tejani Z, Budhani F, et al. R2as a surrogate measure of ferriscan iron quantification in thalassemia. J Magn Reson Imaging. 2013.
154. Kirk P, He T, Anderson LJ, et al. International reproducibility of single breathhold T2MR for cardiac and liver iron assessment among five thalassemia centers. J Magn Reson Imaging. 2010;32:315-319.
155. Tanner MA, He T, Westwood MA, et al. Multi-center validation of the transferability of the magnetic resonance T2technique for the quantification of tissue iron. Haematologica. 2006;91:1388-1391. (Pubitemid 44569814)
156. Tanimoto A, Oshio K, Suematsu M, et al. Relaxation effects of clustered particles. J Magn Reson Imaging. 2001;14:72-77.
157. Weisskoff RM, Zuo CS, Boxerman JL, et al. Microscopic susceptibility variation and transverse relaxation: theory and experiment. Magn Reson Med. 1994;31:601-610. (Pubitemid 24166815)
158. Bowen CV, Zhang X, Saab G, et al. Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson Med. 2002;48:52-61. (Pubitemid 34721587)
159. St Pierre TG, Clark PR, Chua-Anusorn W. Single spin-echo proton transverse relaxometry of iron-loaded liver. NMR Biomed. 2004;17:446-458. (Pubitemid 39549422)
160. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106:1460-1465. (Pubitemid 41129616)
161. Girard OM, Ramirez R, McCarty S, et al. Toward absolute quantification of iron oxide nanoparticles as well as cell internalized fraction using multiparametric MRI. Contrast Media Mol Imaging. 2012;7:411-417.
162. Ghugre NR, Coates TD, Nelson MD, et al. Mechanisms of tissue-iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med. 2005;54:1185-1193. (Pubitemid 41567198)
163. Song R, Lin W, Chen Q, et al. Relationships between MR transverse relaxation parameters R(2), R(2) and R'(2) and hepatic iron content in thalassemic mice at 1.5 T and 3 T. NMR Biomed. 2008;21:574-580.
164. Wood JC, Fassler JD, Meade T. Mimicking liver iron overload using liposomal ferritin preparations. Magn Reson Med. 2004;51:607-611. (Pubitemid 38298676)
165. Jensen JH, Chandra R. Theory of nonexponential NMR signal decay in liver with iron overload or superparamagnetic iron oxide particles. Magn Reson Med. 2002;47:1131-1138. (Pubitemid 34587404)
166. St Pierre TG, El-Beshlawy A, Elalfy M, et al. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. Magn Reson Med. 2013.
167. Marro K, Otto R, Kolokythas O, et al. A simulation-based comparison of two methods for determining relaxation rates from relaxometry images. Magn Reson Imaging. 2011;29:497-506.
168. Doneva M, Bornert P, Eggers H, et al. Compressed sensing reconstruction for magnetic resonance parameter mapping. Magn Reson Med. 2010;64:1114-1120.
169. Feng L, Otazo R, Jung H, et al. Accelerated cardiac T2 mapping using breath-hold multiecho fast spin-echo pulse sequence with k-t FOCUSS. Magn Reson Med. 2011;65:1661-1669.
170. Pell GS, Briellmann RS, Waites AB, et al. Optimized clinical T2 relaxometry with a standard CPMG sequence. J Magn Reson Imaging. 2006;23:248-252. (Pubitemid 43191082)
171. Guo H, Au WY, Cheung JS, et al. Myocardial T2 quantitation in patients with iron overload at 3 Tesla. J Magn Reson Imaging. 2009;30:394-400.
172. Gossuin Y, Muller RN, Gillis P. Relaxation induced by ferritin: a better understanding for an improved MRI iron quantification. NMR Biomed. 2004;17:427-432. (Pubitemid 39549420)
173. Storey P, Thompson AA, Carqueville CL, et al. R2imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging. 2007;25:540-547. (Pubitemid 46355416)
174. Chappell KE, Patel N, Gatehouse PD, et al. Magnetic resonance imaging of the liver with ultrashort TE (UTE) pulse sequences. J Magn Reson Imaging. 2003;18:709-713. (Pubitemid 37467272)
175. Brittenham GM, Farrell DE, Harris JW, et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med. 1982;307:1671-1675
176. Sheth S. SQUID biosusceptometry in the measurement of hepatic iron. Pediatr Radiol. 2003;33:373-377. (Pubitemid 36748389)
177. Maliken BD, Avrin WF, Nelson JE, et al. Room-temperature susceptometry predicts biopsy-determined hepatic iron in patients with elevated serum ferritin. Ann Hepatol. 2012;11:77-84.
178. Hernando D, Cook RJ, Diamond C, et al. Magnetic susceptibility as a B field strength independent MRI biomarker of liver iron overload. Magn Reson Med. 2013.
179. Wang ZJ, Li S, Haselgrove JC. Magnetic resonance imaging measurement of volume magnetic susceptibility using a boundary condition. J Magn Reson. 1999;140:477-481. (Pubitemid 129608310)
180. Taylor BA, Loeffler RB, Song R, et al. Simultaneous field and R2 mapping to quantify liver iron content using autoregressive moving average modeling. J Magn Reson Imaging. 2012;35:1125-1132.
181. Wu EX, Kim D, Tosti CL, et al. Magnetic resonance assessment of iron overload by separate measurement of tissue ferritin and hemosiderin iron. Ann N Y Acad Sci. 2010;1202:115-122.
182. Allen PD, St Pierre TG, Chua-anusorn W, et al. Low-frequency low-field magnetic susceptibility of ferritin and hemosiderin. Biochim Biophys Acta. 2000;1500:186-196. (Pubitemid 30060391)
183. Brooks RA, Vymazal J, Goldfarb RB, et al. Relaxometry and magnetometry of ferritin. Magn Reson Med. 1998;40:227-235. (Pubitemid 28361525)
184. Jensen JH, Tang H, Tosti CL, et al. Separate MRI quantification of dispersed (ferritin-like) and aggregated (hemosiderin-like) storage iron. Magn Reson Med. 2010;63:1201-1209.
185. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep. 2003;5:18-25. (Pubitemid 38899267)
186. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol. 1999;31:421-429. (Pubitemid 29408723)
187. Kohgo Y, Ohtake T, Ikuta K, et al. Dystegulation of systemic iron metabolism in alcoholic liver diseases. J Gastroenterol Hepatol. 2008;23:S78-S81. (Pubitemid 351389036)
188. Sikorska K, Stalke P, Romanowski T, et al. Liver steatosis correlates with iron overload but not with HFE gene mutations in chronic hepatitis C. Hepatobiliary Pancreat Dis Int. 2013;12:377-384.
189. Nelson JE,Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011;53:448-457.
190. Corradini E, Pietrangelo A. Iron and steatohepatitis. J Gastroenterol Hepatol. 2012;27(suppl 2):42-46.
191. Armutcu F, Akyol S, Ucar F, et al. Markers in nonalcoholic steatohepatitis. Adv Clin Chem. 2013;61:67-125.
192. Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis. 2007;11:173-189. (Pubitemid 46829972)
193. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology. 2005;42:5-13. (Pubitemid 40911303)
194. Levenson H, Greensite F, Hoefs J, et al. Fatty infiltration of the liver: quantification with phase-contrast MR imaging at 1.5 T vs biopsy. AJR Am J Roentgenol. 1991;156:307-312.
195. Lim RP, Tuvia K, Hajdu CH, et al. Quantification of hepatic iron deposition in patients with liver disease: comparison of chemical shift imaging with single-echo T2-weighted imaging. AJR Am J Roentgenol. 2010;194:1288-1295.
196. Virtanen JM, Pudas TK, Ratilainen JA, et al. Iron overload: accuracy of in-phase and out-of-phase MRI as a quick method to evaluate liver iron load in haematological malignancies and chronic liver disease. Br J Radiol. 2012;85:e162-e167.
197. Virtanen JM, Komu ME, Parkkola RK. Quantitative liver iron measurement by magnetic resonance imaging: in vitro and in vivo assessment of the liver to muscle signal intensity and the R2methods. Magn Reson Imaging. 2008;26:1175-1182.
198. Boll DT, Marin D, Redmon GM, et al. Pilot study assessing differentiation of steatosis hepatis, hepatic iron overload, and combined disease using two-point dixon MRI at 3 T: in vitro and in vivo results of a 2D decomposition technique. AJR Am J Roentgenol. 2010;194:964-971.
199. Bashir MR, Merkle EM, Smith AD, et al. Hepatic MR imaging for in vivo differentiation of steatosis, iron deposition and combined storage disorder: single-ratio in/opposed phase analysis vs. dual-ratio Dixon discrimination. Eur J Radiol. 2012;81:e101-e109.
200. Papakonstantinou O, Foufa K, Benekos O, et al. Use of fat suppression in R(2) relaxometry with MRI for the quantification of tissue iron overload in beta-thalassemic patients. Magn Reson Imaging. 2012;30:926-933.
201. Schwenzer NF, Machann J, Haap MM, et al. T2relaxometry in liver, pancreas, and spleen in a healthy cohort of one hundred twenty-nine subjects-correlation with age, gender, and serum ferritin. Invest Radiol. 2008;43:854-860.
202. Sanches-Rocha L, Serpa B, Figueiredo E, et al. Comparison between multi-echo T2with and without fat saturation pulse for quantification of liver iron overload. Magn Reson Imaging. 2013;31:1704-1708.
203. Yu H, McKenzie CA, Shimakawa A, et al. Multiecho reconstruction for simultaneous water-fat decomposition and T2estimation. J Magn Reson Imaging. 2007;26:1153-1161. (Pubitemid 47548182)
204. Hernando D, Kramer JH, Reeder SB. Multipeak fat-corrected complex R2relaxometry: theory, optimization, and clinical validation. Magn Reson Med. 2013;70:1319-1331.
205. Lee SS, Lee Y, Kim N, et al. Hepatic fat quantification using chemical shift MR imaging and MR spectroscopy in the presence of hepatic iron deposition: validation in phantoms and in patients with chronic liver disease. J Magn Reson Imaging. 2011;33:1390-1398.
206. Hines CD, Agni R, Roen C, et al. Validation of MRI biomarkers of hepatic steatosis in the presence of iron overload in the ob/ob mouse. J Magn Reson Imaging. 2012;35:844-851.
207. Vasanawala SS, Yu H, Shimakawa A, et al. Estimation of liver T(2) in transfusion-related iron overload in patients with weighted least squares T(2) IDEAL. Magn Reson Med. 2012;67:183-190.
208. Reeder SB, Bice EK, Yu H, et al. On the performance of T2correction methods for quantification of hepatic fat content. Magn Reson Med. 2012;67:389-404.
209. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672-679. (Pubitemid 23360802)